Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

Smallpox Clinical Trial

Official title:

A Post Marketing Study of the Safety, Tolerability, and Pharmacokinetics of TPOXX In Adult Subjects Weighing More Than 120 KG

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04392739
• Other study ID #: SIGA-246-022
• Status: Completed
• Phase: Phase 4
• Start date: July 19, 2019
• Est. completion date: December 5, 2019

Study information

• Verified date: May 2020
• Source: SIGA Technologies
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Safety and PK study in adults weighing more than 120 kg

Description:

The primary objective of this study is to determine the pharmacokinetic (PK) profile of 600 mg oral TPOXX (3 × 200-mg capsules) administered twice daily (BID) for 7 days in adult subjects weighing more than 120 kg to determine if a change in dosing regimen would be needed in these patients.

Secondary:

The secondary objective of this study is to evaluate the safety and tolerability of 600 mg oral TPOXX administered BID for 7 days in healthy adult subjects weighing more than 120 kg.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: December 5, 2019
• Est. primary completion date: December 5, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Subject is male or female between 18 and 50 years of age, inclusive.

2. Subject has a body weight >120 kg at screening, at check-in on Day -1, and prior to dosing on Day 1.

3. Women of childbearing potential, have a negative ß human chorionic gonadotropin pregnancy test (serum) at the screening visit and a confirmatory negative serum pregnancy test on Day -1 before receipt of study drug, and meet 1 of the following criteria:

1. The subject or their partner has undergone surgical sterilization

2. The subject is postmenopausal, defined as 12 consecutive months with no menses without an alternative medical cause and has a documented plasma follicle-stimulating hormone level >40 IU/mL

3. The subject agrees to be abstinent (ie, heterosexually inactive or women in a religious order)

4. The subject agrees to consistently use 1 of the following methods of contraception from the beginning of screening (which they had been consistently using for at least 30 days before the first dose of study drug) through 30 days after the last dose of study drug:

i. Condoms, male or female, with a spermicide NOTE: For male subjects, condoms must be used for 90 days after the last dose of study drug.

ii. Diaphragm or cervical cap with spermicide

iii. Intrauterine device with spermicide

iv. Oral contraceptives or other hormonal methods NOTE: Subject must agree to use an additional nonhormonal method of contraception in conjunction with oral contraceptives.

v. Male sexual partner who had undergone a vasectomy at least 3 months before screening

4. Male subjects must agree to not donate sperm from the first dose of study drug through 90 days after the last dose of study drug.

5. Subject is considered by the investigator to be in good general health as determined by medical history (no hospitalizations for chronic medical conditions in the previous 2 years), clinical laboratory results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at screening.

6. Subject agrees to comply with all protocol requirements.

7. Subject is able to provide written informed consent.

8. Subject agrees to comply with the dietary requirements.

9. Subject does not intend to lose

Exclusion Criteria:

Subjects meeting any of the following criteria will be excluded from the study:

1. Subject is a female who is pregnant or breastfeeding or planning to become pregnant within 3 months after the last dose of study drug.

2. Subject has a history of any clinically significant conditions including:

• Asthma treated with oral systemic steroids within the past 6 months

• Diabetes mellitus (type 1 or 2), with the exception of gestational diabetes

• Thyroidectomy or thyroid disease that required medication within the past 12 months

• Serious angioedema episodes within the previous 3 years or requiring medication in the previous 2 years

• Head trauma resulting in a diagnosis of traumatic brain injury other than concussion

• Frequent episodes of headache.

3. Subject has received treatment in another clinical study of an investigational drug (or medical device) within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug.

4. Subject has been previously enrolled in any clinical study involving TPOXX (tecovirimat).

5. Subject has a history of relevant drug and/or food allergies (ie, allergy to tecovirimat or excipients, or any significant food allergy that could preclude a standard diet in the study site).

6. Subject has any condition possibly affecting drug absorption (eg, previous surgery on the gastrointestinal tract, including removal of parts of the stomach, bowel, liver, gallbladder, or pancreas, with the exception of appendectomy).

7. Subject has evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of the first dose of study drug), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease. Exceptions to these criteria (eg, stable, mild joint disease unassociated with collagen vascular disease) may be made following discussions with the medical monitor.

Page 10

8. Subject has a history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or risk factors for torsades de pointes (eg, heart failure, hypokalemia).

9. Subject has a family history of sudden cardiac death, not clearly due to acute myocardial infarction.

10. Subject has a seizure disorder or history of seizures (does not include childhood febrile seizures) or a past history that increases seizure risks such as significant head injury that caused loss of consciousness or other changes in the subject's daily function, concussion, stroke, central nervous system infection or disease, or alcohol or drug abuse or family history of idiopathic seizures.

11. Subject has a history of a peptic ulcer or significant gastrointestinal bleed.

12. Subject has a bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with blood draws.

13. Subject has a malignancy that is active, or treated malignancy for which there is not reasonable assurance of sustained cure, or malignancy that is likely to recur during the period of the study (subject should be in complete remission for at least 5 years).

14. Subject has neutropenia or other blood dyscrasia determined to be clinically significant by the investigator.

15. Subject has used any of the following prohibited medications from within 7 days (or 5 half-lives, whichever is longer) before the first dose of study drug: antidiabetic medication; anticoagulants; anticonvulsants; substrates of the breast cancer resistance protein transporter including methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, and topotecan; substrates of CYP2C8 including repaglinide, paclitaxel, Montelukast, pioglitazone, rosiglitazone; and substrates of CYP2C19 including S-mephenytoin, clobazam, diazepam, rabeprazole, voriconazole, lansoprazole, and omeprazole. Medications not listed here that are known (or thought) to be CYP3A4 substrates may be allowed at the investigator's discretion, after consultation with the medical monitor, if administration poses little to no risk to the subject.

16. Subject has a history of drug or alcohol abuse or dependency within the last year before screening.

17. Subject has a history of an eating disorder.

18. Subject has a current or recent (<30 days before screening) history of clinically significant bacterial, fungal, or mycobacterial infection.

19. Subject has a current clinically significant viral infection.

20. Subject has a known clinically significant chronic viral infection (eg, human T cell lymphotropic virus I or II).

21. Subject has consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or caffeine- or xanthine-containing products within 48 hours before the first dose of study drug or throughout the study.

22. Subject has used any prescription (excluding hormonal birth control) or over-the-counter medication (including herbal or nutritional supplements) within 14 days before the first dose of study drug.

23. Subject demonstrates long-term use (=14 consecutive days) of glucocorticoids including oral or parenteral prednisone or equivalent (>20 mg total dose per day) or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 1 month (low-dose [=800 mcg/day of beclomethasone dipropionate or equivalent] inhaled and topical steroids are allowed).

24. Subject has donated >450 mL blood or blood components within 30 days before the first dose of study drug. The investigator should instruct subjects who participate in this study to not donate blood or blood components for 4 weeks after the completion of the study.

25. Subject is a smoker or has used nicotine or nicotine-containing products (eg, cigarettes, electronic vapor cigarettes, cigars, chewing tobacco, snuff, nicotine patches, or nicotine gum) within 6 months before the first dose of study drug.

26. Subject has consumed pomegranate or pomegranate juice, pomelo fruits or pomelo juice, or alcohol within 72 hours before the first dose of study drug.

27. Subject reports participation in strenuous activity or contact sports within 24 hours before the first dose of study drug.

28. Subject has known hepatitis B or C infection or positive test for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus type 1 or 2 antibodies at screening.

29. Subject has a positive test result for amphetamines (including methamphetamines and ecstasy/methylenedioxymethamphetamine), barbiturates, benzodiazepines, cannabinoids (including tetrahydrocannabinol), cocaine metabolites, opiates (including heroin, codeine, and oxycodone), or alcohol at screening or check-in.

30. Subject has any of the following laboratory test results within 28 days before the first dose of study drug:

• Estimated serum creatinine clearance (Cockcroft-Gault) <90 mL/min

• Creatinine in males >1.7 mg/dL and in females >1.4 mg/dL (1.3 times the upper central laboratory reference range)

• Hemoglobin =10% of the lower central laboratory reference range

• White blood cell count not within the central laboratory reference range

• Absolute neutrophil count <1000 cells/mm3

• Platelets not within ±10% of central laboratory reference range

• Alanine aminotransferase >1.5 times above the upper central laboratory reference range

• Aspartate aminotransferase >1.5 times above the upper central laboratory reference range

• Alkaline phosphatase >20% above the upper central laboratory reference range

• Hemoglobin A1c =7.0%

• Cholesterol =300 mg/dL and low-density lipoprotein =190 mg/dL.

31. Subject has a blood pressure considered to be clinically significant by the investigator. Blood pressure may be retested twice in the sitting position at 5-minute intervals.

32. Subject has a resting heart rate of <40 beats per minute or >100 beats per minute at screening.

33. Subject has an abnormal ECG at screening that is determined by the investigator to be clinically significant.

34. Male subject has a QTcF >450 ms or female subject has a QTcF >470 ms at screening or Day -1.

35. In the opinion of the investigator, the subject is not suitable for entry into the study.

Related Conditions & MeSH terms

• Smallpox

Intervention

Drug:
• Tpoxx
oral antiviral

Locations

Country	Name	City	State
United States	PPD Phase I Clinic	Austin	Texas

Sponsors (3)

Lead Sponsor	Collaborator
SIGA Technologies	Biomedical Advanced Research and Development Authority, PPD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration vs. time curve (AUC) from time 0 to the last quantifiable measurement (AUC0-t)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	AUC from time 0 to 24 hours postdose (AUC0-24).	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	AUC during the first dosing interval (AUC0-tau; tau = 12 hours)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	AUC from time 0 extrapolated to infinity (AUC0-inf)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	Percentage of AUC0-inf extrapolated from the last quantifiable measurement to infinity (%AUCextrap)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	Maximum observed plasma drug concentration (Cmax)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	Time to reach Cmax (Tmax)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	Terminal elimination rate constant (?z)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	Terminal elimination half-life (t1/2)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	Apparent total body clearance (CL/F)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	Apparent volume of distribution (Vd/F)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Primary	Concentration observed prior to the next dose administration (Ctrough)	PK Parameter	Blood samples for PK analysis of TPOXX were collected on the following study days: Day 1, Day 2, Day 6, Day , Day 8 and Day 9
Secondary	Number of subjects with AEs as assessed by CTCAE	monitoring and collection of adverse events	30 days
Secondary	Percentages of subjects with AEs	Monitoring and collection of AEs	30 days
Secondary	Changes in hematology values	hematology	9 days
Secondary	Changes in serum chemistry values	serum chemistry	9 days
Secondary	Changes in urinalysis results	urinalysis	9 days
Secondary	Summary of observed values and changes in blood pressure in mmHg using a sphygmomanometer from baseline and to each post-baseline visit	systolic and diastolic blood pressures	9 days
Secondary	Summary of observed values and changes in hear rate per in beats per minute from baseline and to each post-baseline visit	heart rate	9 days
Secondary	Summary of observed values and changes in respiratory rate per minute from baseline and to each post-baseline visit	respiratory rate	9 days
Secondary	Monitoring and recording of body temperature recorded in Centigrade	body temperature	9 days
Secondary	Summary of observed values and changes in ECG reading and interpretation including ECG QT interval from baseline and to each post-baseline visit using an electrocardiograph	12 -lead ECG	9 days
Secondary	Summary of observed physical exam changes from baseline and to each post-baseline visit; body system assessment	physical examination	9 days